Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016

  • ID: 3802752
  • Report
  • 44 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abivax S.A.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Transgene SA
  • VLP Biotech, Inc.
  • MORE
Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016

Summary

‘Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016’, provides in depth analysis on Hepatitis B Virus Core Antigen (HBcAg) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatitis B Virus Core Antigen (HBcAg), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatitis B Virus Core Antigen (HBcAg)
- The report reviews Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatitis B Virus Core Antigen (HBcAg)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis B Virus Core Antigen (HBcAg) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abivax S.A.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Transgene SA
  • VLP Biotech, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hepatitis B Virus Core Antigen (HBcAg) Overview

Therapeutics Development

Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Stage of Development

Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Therapy Area

Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Indication

Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Companies

Hepatitis B Virus Core Antigen (HBcAg) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis B Virus Core Antigen (HBcAg) - Companies Involved in Therapeutics Development

Abivax S.A.

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Transgene SA

VLP Biotech, Inc.

Hepatitis B Virus Core Antigen (HBcAg) - Drug Profiles

ABX-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-4774 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7944 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-1050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis B Virus Core Antigen (HBcAg) - Dormant Projects

Hepatitis B Virus Core Antigen (HBcAg) - Featured News & Press Releases

Dec 08, 2015: ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B

Nov 04, 2015: Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection

May 27, 2015: GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients

Apr 23, 2015: Transgene Presents New Data with TG1050, an Immunotherapy Being Developed to Treat Chronic Hepatitis B, at The International Liver Congress 2015

Apr 21, 2015: Inovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infection

Feb 26, 2015: ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B

Jul 01, 2014: Transgene Announces Presentation of Data on TG1050 Immunotherapy against Chronic Hepatitis B

Nov 05, 2013: Transgene Announces Data on TG1050 Presented at Recent Medical and Scientific Conferences

Apr 29, 2013: Transgene Presents Positive Preclinical Data On TG1050 To Treat Chronic HBV At EASL 2013

Apr 08, 2013: Transgene To Present New Data On TG1050 To Treat Chronic Hepatitis B At EASL 2013 Conference

Jan 28, 2013: GlobeImmune Initiates Phase Ia Clinical Trial Of GI-13020 In Healthy Volunteers

Nov 12, 2012: Inovio Pharma's Hepatitis B Vaccine Demonstrates Potential To Clear Hepatitis B Virus In Liver In Preclinical Study

Nov 12, 2012: Inovio Pharma's Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential To Clear HBV In Liver

Apr 19, 2012: Transgene’s New Therapeutic Vaccine Candidate to Treat Chronic Hepatitis B Reaches Preclinical Proof of Concept

Oct 10, 2011: Inovio Pharma And VGX International To Advance Therapeutic Hepatitis C And Hepatitis B Synthetic Vaccines Into Clinical Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 44List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Abivax S.A., H1 2016

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pipeline by Gilead Sciences, Inc., H1 2016

Pipeline by Transgene SA, H1 2016

Pipeline by VLP Biotech, Inc., H1 2016

Dormant Projects, H1 2016 31List of Figures

Number of Products under Development for, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abivax S.A.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Transgene SA
  • VLP Biotech, Inc.
  • MORE
According to the author's, recently published report 'Hepatitis B Virus Core Antigen - Pipeline Review, H1 2016'; Hepatitis B Virus Core Antigen (HBcAg) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Furthermore, the author says; Hepatitis B Virus Core Antigen (HBcAg) HBcAg (core antigen) is a hepatitis B viral protein. It plays an important role in viral replication. It is found on the surface of the nucleocapsid core of hepatitis B virus.

The report 'Hepatitis B Virus Core Antigen - Pipeline Review, H1 2016' outlays comprehensive information on the Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 1 respectively.
Note: Product cover images may vary from those shown
5 of 5
Abivax S.A.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Transgene SA
VLP Biotech, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll